This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NeoStem, Inc., a clinical-stage biopharmaceutical company, develops cell based therapeutics in the United States.View NBS key stats
Neostem Inc - NBS - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Neostem Inc as a
Sell with a ratings score of D-.
Report Snippet: We rate NEOSTEM INC (NBS) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, poor profit margins, weak operating cash flow and generally disappointing historical performance in the stock itself.